Related Experiment Video
Updated: Apr 12, 2026
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Relation between prognosis and changes of MBP and S100B in premature infants with periventricular leukomalacia
R Z Huang1, Y J Zhang2, J F Zhang2
1Department of Pediatrics, Maternal and Child Healthcare of Shunde District, Foshan, Guangdong Province, China RunzhongHuang@126.com.
Insights
Elevated serum levels of myelin basic protein (MBP) and S100 protein (S100B) in premature infants with periventricular leukomalacia (PVL) indicate a poor prognosis. Persistent high levels beyond seven days suggest worse neurodevelopmental outcomes.
Area of Science:
- Biochemistry
- Neonatology
- Neurology
Background:
- Periventricular leukomalacia (PVL) is a common form of brain injury in premature infants.
- Biomarkers may help predict neurodevelopmental outcomes in these infants.
Purpose of the Study:
- To investigate the relationship between serum levels of myelin basic protein (MBP) and S100 protein (S100B) and the prognosis of premature infants with PVL.
- To assess the correlation between these biomarkers and neurodevelopmental outcomes.
Main Methods:
- Serum MBP and S100B levels were measured using enzyme-linked immunosorbent assay in 78 premature infants with PVL and 43 controls at 1, 3, 7, and 14 days post-birth.
- Infants were followed for neurodevelopmental assessment using Gesell developmental scales.
Main Results:
- Premature infants with PVL showed significantly higher MBP levels than controls at all time points.
- S100B levels peaked on day 7 and then decreased.
- Elevated MBP and S100B levels on day 7 were associated with lower intelligence quotient and physical development index.
Conclusions:
- Increased MBP and S100B serum levels are associated with poor prognosis in premature infants with PVL.
- Sustained elevation of these biomarkers beyond 7 days may predict adverse neurodevelopmental outcomes.
Abstract:
This study aims to explore the relation between changes in myelin basic protein (MBP) and S100 protein (S100B) serum levels and prognosis in premature infants with periventricular leukomalacia (PVL). In our hospital, 78 premature infants with PVL and 43 normal premature infants were studied from July 1, 2007 to December 31, 2008. MBP and S100B serum levels were detected at 1, 3, 7, and 14 days after birth by using enzyme-linked immunosorbent assay. All infants were followed four times (once every 3 months) after discharge from hospital. Their intelligence quotient and physical development index were tested by using Gesell developmental scales. The MBP serum levels were significantly higher in premature infants with PVL at any time point than in normal premature infants. S100B serum levels gradually increased at 1, 3, and 7 days; peaked on the 7th day; and then gradually decreased to the normal level on the 14th day. The intelligence quatient and physical development index of infants with increased S100B and MBP levels on the 7th day were lower than those of infants who had normal S100B and MBP levels and those of normal premature infants. A negative relation exists between S100B and MBP serum levels and prognosis in PVL infants. An increase of MBP and S100B levels lasting >7 days could cause poor prognosis.
